Restructuring and Other Costs (Income), Net (Tables)

6 Months Ended

Jun. 29, 2019

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs [Table Text Block]

During the second quarter of 2019, the company recorded net restructuring and other costs (income) by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs (Income), Net			Total
Life Sciences Solutions	$	5	$	—	$	8		$	13
Analytical Instruments	—		18		5			23
Specialty Diagnostics	—		—		(504		)	(504		)
Laboratory Products and Services	—		18		6			24
Corporate	—		—		1			1
	$	5	$	36	$	(484	)	$	(443	)

During the first six months of 2019, the company recorded net restructuring and other costs (income) by segment as follows:

(In millions)	Cost of Revenues		Selling, General and Administrative Expenses		Restructuring and Other Costs (Income), Net			Total
Life Sciences Solutions	$	11	$	—	$	11		$	22
Analytical Instruments	—		24		9			33
Specialty Diagnostics	—		4		(503		)	(499		)
Laboratory Products and Services	—		19		8			27
Corporate	—		—		2			2
	$	11	$	47	$	(473	)	$	(415	)

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs (income), net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.

(In millions)	Severance			Abandonment of Excess Facilities			Other (a)			Total
Balance at December 31, 2018	$	34		$	42		$	4		$	80
Cumulative effect of accounting change (b)	—			(28		)	—			(28		)
Costs incurred in 2019 (d)	13			3			7			23
Reserves reversed (c)	(1		)	(1		)	—			(2		)
Payments	(20		)	(7		)	(7		)	(34		)
Balance at June 29, 2019	$	26		$	9		$	4		$	39

(a) Other includes relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

(b) Impact of adopting new lease accounting guidance on January 1, 2019.

(c) Represents reductions in cost of plans.

(d)

Excludes $505 million gain on the sale of the company's Anatomical Pathology business; $6 million of impairment of acquired in-process research and development; $3 million of compensation due to employees on the date of acquisition; and $2 million of other non-cash charges, net.